

Update on Pharmacoeconomics in the Irish Healthcare Setting



Date: 15th & 16th May 2019
Venue: Hibernia Centre, Dublin Castle

DAY ONE

Registration and tea/coffee on arrival from 8.15 am

DESCRIPTION	SPEAKER	TIME
Opening	Minister Simon Harris	9.00
Session 1 – Drugs for Rare Diseases: Recent Developments in Assessment and Engagement		9.30
Overview of NCPE Patient Engagement Activities	Claire Gorry, NCPE	
Orphan Drug Submissions to the NCPE	Dr Cara Usher, NCPE	
Stakeholder Engagement for the Rare Disease Technology Review Group	Alma Hanevy, NCPE	
The Patient Perspective	Bernadette Gilroy, PKU Society	
Coffee Break		11.00
Session 2 - Assessing Advanced Therapeutic Medicinal Products – Perspectives and Considerations		11.30
Introduction to Advanced Therapy Medicinal Products	Dr Roisin Adams, NCPE	
Gene Therapies - The Clinical Perspective	Dr Larry Bacon, Consultant Haematologist, St James's Hospital	
Institutional Requirements for the Provision of a CAR T-Cell Service: a HTA Review	Niamh Carey, NCPE	
Lunch		13.00
Session 3 – Future of HTA and Healthcare Funding - Stakeholder Perspectives		14.00
National Centre for Pharmacoeconomics	Prof Michael Barry, Director of the NCPE	
Irish Pharmaceutical Healthcare Association	Aidan Lynch, IPHA President	
Drugs Group / National Cancer Control Programme	Dr Jerome Coffey, Director of the NCCP	
Primary Care Reimbursement Service, HSE	Anne-Marie Hoey, Director of the PCRS	
Acute Hospitals, HSE	Dr Roisin Adams, NCPE	
Questions and Answers	All	
Afternoon Close		16.00

Update on Pharmacoeconomics in the Irish Healthcare Setting



DAY TWO

Tea/coffee on arrival from 8.15 am

DESCRIPTION	SPEAKER	TIME
Session 1 – Recent Developments at the NCPE		9.00
NCPE process update: Overview of NCPE Rapid Review / HTA Process	Dr Lesley Tilson, NCPE	
An Analysis of Rapid Review and HTA Timelines	Emma Connolly, NCPE	
Development of Plain English Summaries and Website Developments	Alma Hanevy, NCPE	
Budget Impact Template	Dr Felicity Lamrock, NCPE	
NCPE Critical Appraisal of Economic Models	Dr Felicity Lamrock, NCPE	
Tips for Improving the Quality of an Excel Model for Submission	Dr Joy Leahy, NCPE	
Process for Internal Validation of Sensitivity Analysis	Dr Joy Leahy, NCPE	
Coffee Break		11.00
Session 2 – Research / Medicines Management Programme / European Initiatives		11.30
Ongoing research at NCPE:		
Cost effectiveness of Treatment Strategies for Skin Cancer	Claire Gorry, NCPE	
Research in HTA methodology: Application to the PCSK9 inhibitors	Helen O'Donnell, NCPE	
Update on Medicines Management Programme:		
Reimbursement Application System for the PCSK9 inhibitors	Prof Michael Barry, NCPE	
European Initiatives:		
Issues in Medicines Policy for 2019	Dr Roisin Adams, NCPE	
Lunch		13.00
Session 3 – NCPE HTA Discussion Group		14.00
Issues Arising from HTA submissions to the NCPE	Dr Laura McCullagh, NCPE Dr Arthur White, NCPE /Trinity College Dublin Others TBC	
Session 4 – HTA of Drugs with Limited Evidence		15.00
Clinical Considerations	Dr Aisling O'Leary, NCPE	
Statistical Considerations	Prof Cathal Walsh, Professor of Statistics, University of Limerick	
Matched Adjusted Indirect Comparison: What We Expect in a HTA Submission	Dr Joy Leahy, NCPE	
Closing Remarks	Prof Michael Barry	16.00